Evidence map›Paper›PMID 39649998›Full record

ReviewACS organic & inorganic Au2024

The Future of Electro-organic Synthesis in Drug Discovery and Early Development.

H R Stephen, J L Röckl

Abstract readReview
In one paragraph

Review in ACS organic & inorganic Au, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Electrochemical Hydrogenation of Aza-Arenes Using HJournal of the American Chemical Society · 2026
    Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

H R StephenChemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, United Kingdom.ORCID https://orcid.org/0000-0002-0392-4300
J L RöcklMedicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, SE-431 83 Mölndal, Sweden.ORCID https://orcid.org/0000-0001-8371-1817

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Electro-organic chemistry presents a promising frontier in drug discovery and early development, facilitating novel reactivity aligned with green chemistry principles. Despite this, electrochemistry is not widely used as a synthesis and manufacturing tool in drug discovery or development. This overview seeks to identify key areas that require additional research to make synthetic electrochemistry more accessible to chemists in drug discovery and early development and provide potential solutions. This includes expanding the reaction scope, simplifying rapid scale-up, developing electrode materials, and improving knowledge transfer to aid reproducibility and increase the awareness of electrochemistry. The integration of electro-organic synthesis into drug discovery and development holds the potential to enable efficient, sustainable routes toward future medicines faster than ever.

Identifiers

PMID39649998
PMCPMC11621954

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.